A split-face study using Botulinum Toxin type B to decrease facial Erythema index

Journal of Cosmetic and Laser Therapy

Volumn 13, Issue 5, 2011, Pages 243-248

  Oh, Yu Jin ^a   Lee, Na Young ^c   Suh, Dong Hye ^c   Koh, Jea Sook ^b   Lee, Sang Jun ^c   Shin, Min Kyung ^a  

^a Kyung Hee University Hospital   (South Korea)

^b Dermapro Ltd   (South Korea)

^c Arumdaun Nara Dermatologic Clinic   (South Korea)

Author keywords

botulinum; erythema; flushing; mexameter; myobloc

Indexed keywords

BOTULINUM TOXIN B; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FACE ERYTHEMA; FACIAL ERYTHEMA INDEX; FEMALE; FLUSHING; HUMAN; INFECTION; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; MALE; MUSCLE DISEASE; NEUROPATHY; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SELF EVALUATION;

ADULT; BOTULINUM TOXINS; DOUBLE-BLIND METHOD; ERYTHEMA; FEMALE; FLUSHING; HUMANS; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PATIENT SATISFACTION; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 80052979021     PISSN: 14764172     EISSN: 14764180     Source Type: Journal    
DOI: 10.3109/14764172.2011.613479     Document Type: Article

References (27)

1. Low DA, Hubing KA, Del Coso J, Crandall CG. Mechanisms of cutaneous vasodilation during the postmenopausal hot flash. Menopause. 2010.
2. Sterodimas A, Nicolaou M, Paes TR. Successful use of Botulinum toxin-A for the treatment of neck and anterior chest wall flushing. Clin Exp Dermatol. 2003;28:592-594. (Pubitemid 37430875)
3. Yuraitis M, Jacob CI. Botulinum toxin for the treatment of facial flushing. Dermatol Surg. 2004;30:102-104. (Pubitemid 38174039)
4. Pierard GE. EEMCO guidance for the assessment of skin colour. J Eur Acad Dermatol Venereol. 1998;10:1-11. (Pubitemid 28076349)
5. Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol. 2006;13(Suppl 1):11-15.
6. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29:1761-1768. (Pubitemid 350176807)
7. Aoki KR. Pharmacology and immunology of botulinum neurotoxins. Int Ophthalmol Clin. 2005;45:25-37. (Pubitemid 41022173)
8. Arat YO, Yen MT. Effect of botulinum toxin type a on tear production after treatment of lateral canthal rhytids. Ophthal Plast Reconstr Surg. 2007;23:22-24. (Pubitemid 46146892)
9. Fagien S, Cox SE, Finn JC, Werschler WP, Kowalski JW. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo- controlled study. Dermatol Surg. 2007;33:S2-S9. (Pubitemid 46051393)
10. Hui JI, Lee WW. Efficacy of fresh versus refrigerated botulinum toxin in the treatment of lateral periorbital rhytids. Ophthal Plast Reconstr Surg. 2007;23:433-438. (Pubitemid 350146480)
11. de Boulle K. Patient satisfaction with different botulinum toxin type A formulations in the treatment of moderate to severe upper facial rhytids. J Cosmet Laser Ther. 2008;10: 87-92. (Pubitemid 351883324)
12. Carruthers A, Carruthers J. A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. J Am Acad Dermatol. 2009;60:972-979.
13. Wollina U, Karamfilov T. Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison. J Eur Acad Dermatol Venereol. 2002;16:40-42. (Pubitemid 34202001)
14. Klein AW. Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. J Am Acad Dermatol. 2004;50:153 - 154; author reply 154.
15. Swartling C, Naver H, Lindberg M, Anveden I. Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. J Am Acad Dermatol. 2002;47:667-671. (Pubitemid 35239326)
16. Frasson E, Brigo F, Acler M, Didone G, Vicentini S, et al. Botulinum toxin type A vs type B for axillary hyperhidrosis in a case series of patients observed for 6 months. Arch Dermatol. 2011;147:122-123.
17. Campanati A, Sandroni L, Gesuita R, Giuliano A, Giuliodori K, et al. Treatment of focal idiopathic hyperhidrosis with Botulinum Toxin Type A: clinical predictive factors of relapsefree survival. J Eur Acad Dermatol Venereol. 2010.
18. Bosdotter Enroth S, Rystedt A, Covaciu L, Hymnelius K, Rystedt E, et al. Bilateral forearm intravenous regional anesthesia with prilocaine for botulinum toxin treatment of palmar hyperhidrosis. J Am Acad Dermatol. 2010;63:466-474.
19. Gregoriou S, Rigopoulos D, Makris M, Liakou A, Agiosofitou E, et al. Effects of botulinum toxin-a therapy for palmar hyperhidrosis in plantar sweat production. Dermatol Surg. 2010;36:496-498.
20. Coutinho dos Santos LH, Gomes AM, Giraldi S, Abagge KT, Marinoni LP. Palmar hyperhidrosis: long-term follow-up of nine children and adolescents treated with botulinum toxin type A. Pediatr Dermatol. 2009;26:439-444.
21. Wang CC, Wang CP. Preliminary experience with botulinum toxin type A intracutaneous injection for Frey's syndrome. J Chin Med Assoc. 2005;68:463-467.
22. Ng S, Torjek C, Hovan A. Management of Frey syndrome using botulinum neurotoxin: a case report. J Can Dent Assoc. 2009;75:651-654.
23. Cantarella G, Berlusconi A, Mele V, Cogiamanian F, Barbieri S. Treatment of Frey's syndrome with botulinum toxin type B. Otolaryngol Head Neck Surg. 2010;143:214-218.
24. Tugnoli V, Marchese Ragona R, Eleopra R, Quatrale R, Capone JG, et al. The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A. Clin Auton Res. 2002;12:174-178. (Pubitemid 34994577)
25. Kranendonk SK, Ferris LK, Obagi S. Re: Botulinum toxin for the treatment of facial flushing. Dermatol Surg. 2005;31:491; author reply 492.
26. Alexandroff AB, Sinclair SA, Langtry JA. Successful use of botulinum toxin a for the treatment of neck and anterior chest wall flushing. Dermatol Surg. 2006;32:1536. (Pubitemid 44934912)
27. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol. 2009;256: 563-567.